Skip to main content
. 2018 Nov 28;18(3):437–447. doi: 10.1074/mcp.RA118.000957

Fig. 5.

Fig. 5.

Cell proliferation rate measurement of 293T and the isogenic SETD2 KO cells after shRNA- or siRNA-mediated knockdown of PLK1, CCNB1 or CDK1, or treatment with a PLK1 inhibitor (GSK461364). A, Interaction network of targets from RNA-seq and quantitative proteomic analysis of chromatin-binding proteins in PLK1-CDK1 pathway. Blue, potential tumor targets from RNA-seq; Red, potential tumor targets based on results about chromatin-binding proteins. The size of the nodes is proportional to the interaction numbers of each nodes. B, Proliferation of 293T and SETD2 KO cells after knockdown of PLK1, CCNB1, CDK1 or treatment with a PLK1 inhibitor (GSK461364, GSK).